DVA

Business Context and Reporting Period

Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: DaVita is a leading provider of dialysis services in the United States. The company operates outpatient dialysis centers and provides related services, with a significant portion of revenue derived from government programs (Medicare/Medicaid) and private payors.

Key Financial Metrics

Margins: Operating margin was approximately 17.4% for Q1 2005 compared to 18.1% in Q1 2004. Patient care costs represented 67% of net operating revenues.

Material Changes vs. Prior Period

• Revenue Growth: Net operating revenues increased by $74.5 million (14%) year-over-year, driven by a 12% increase in dialysis treatments (5.6% organic growth, 6.4% from acquisitions) and a 2% increase in ancillary revenue.
• Expense Increases: General and administrative expenses rose by $11.7 million year-over-year, attributed to organizational infrastructure expansion and legal/compliance fees. Patient care costs remained stable on a per-treatment basis.
• Debt Restructuring: On March 22, 2005, the company issued $1.35 billion in new senior notes ($500M due 2013, $850M due 2015) to repay all outstanding term loans. This resulted in $6.9 million in refinancing charges and the reclassification of $8.4 million in swap valuation gains to net income.
• Liquidity: Cash and cash equivalents increased by $65.9 million during the quarter, ending at $317.9 million.

Guidance, Outlook, and Risks

Outlook and Guidance

• 2005 Operating Income: Management targets operating income to be 2% to 6% higher than 2004 levels, excluding the impact of the pending Gambro Healthcare acquisition.
• Gambro Acquisition Impact: The acquisition of Gambro Healthcare (approx. $3.05 billion) is expected to be dilutive to EPS in the first year post-closing, neutral in the second year, and accretive thereafter.
• Capital Expenditures: Expected to range between $100 million and $120 million for 2005.

Material Risks and Contingencies

• Government Investigations: The company is subject to three active subpoenas from U.S. Attorney's Offices (Missouri, New York, Pennsylvania) regarding billing practices, pharmaceutical services, and financial relationships with physicians. These are joint civil and criminal investigations with potential for substantial penalties or exclusion from government programs.
• Regulatory Changes: Risks include potential reductions in Medicare/Medicaid reimbursement rates, changes in the composite rate structure, and stricter enforcement of anti-kickback and Stark II laws.
• Pharmaceutical Costs: Approximately 40% of revenues are tied to pharmaceuticals (e.g., EPO). Risks include price increases by suppliers (Amgen) and the introduction of new drugs (Aranesp) that may alter administration patterns and margins.
• Acquisition Integration: The Gambro Healthcare acquisition faces antitrust review (FTC), with an expectation to divest approximately 5% of combined centers. Integration risks and unknown liabilities of Gambro are significant.

Investor Verification Checklist

• Debt Service Capacity: Verify the company's ability to service the new $1.35 billion in fixed-rate debt and the anticipated $3.15 billion in new credit facilities for the Gambro acquisition.
• Regulatory Resolution: Monitor the status of the three U.S. Attorney investigations and the potential for fines or exclusion from Medicare/Medicaid.
• FTC Antitrust Review: Confirm the final terms of the Gambro Healthcare acquisition, specifically the extent of required divestitures and the timeline for closing.
• Reimbursement Rates: Track changes in Medicare ESRD composite rates and the impact of the new case-mix adjustment methodology implemented in April 2005.
• Pharmaceutical Mix: Assess the impact of Aranesp adoption and EPO pricing on the 40% of revenue derived from pharmaceuticals.